Herpes Zoster - Pipeline Insight, 2022
This report can be delivered to the clients within 48-72 hours
DelveInsight’s, “Herpes Zoster – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Herpes Zoster pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Herpes Zoster: Overview
Herpes zoster, also known as shingles, is a viral syndrome caused by reactivation of the varicella-zoster virus. After an episode of varicella (chicken-pox), the varicella-zoster virus remains dormant in the nervous system. Herpes zoster typically occurs in adults or elderly. It is believed that zoster occurs due to the failure of the immune defense system to control the latent replication of the virus. Upon reactivation, the virus replicates in neuronal cell bodies, and virions shed from the cells which are carried down the nerve to the area of skin innervated by that ganglion. In the skin, the virus causes local inflammation and blistering. The pain caused by zoster is due to inflammation of affected nerves with the virus. Zoster characteristically presents with a prodrome of fever, malaise, and excruciating burning pain followed by the outbreak of vesicles that appear in one to three crops over three to five days. Lesions are distributed unilaterally within a single dermatome. Herpes zoster is clinically diagnosed with burning pain, characteristic morphology, and typical distribution. Antiviral therapy hastens the resolution of lesions, decreases acute pain and helps to prevent post-herpetic neuralgia especially in elderly patients. Acyclovir 800 mg, five times daily for five days, valacyclovir 1 gm three times daily for five days, and famciclovir 500 mg three times daily for seven days are the antiviral drugs used to treat herpes zoster.
'Herpes Zoster - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Herpes Zoster pipeline landscape is provided which includes the disease overview and Herpes Zoster treatment guidelines. The assessment part of the report embraces, in depth Herpes Zoster commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Herpes Zoster collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Herpes Zoster report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Herpes Zoster Emerging Drugs
Further product details are provided in the report……..
Herpes Zoster: Therapeutic Assessment
This segment of the report provides insights about the different Herpes Zoster drugs segregated based on following parameters that define the scope of the report, such as:
Herpes Zoster: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Herpes Zoster therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Herpes Zoster drugs.
Herpes Zoster Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Herpes Zoster – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Herpes Zoster pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Herpes Zoster: Overview
Herpes zoster, also known as shingles, is a viral syndrome caused by reactivation of the varicella-zoster virus. After an episode of varicella (chicken-pox), the varicella-zoster virus remains dormant in the nervous system. Herpes zoster typically occurs in adults or elderly. It is believed that zoster occurs due to the failure of the immune defense system to control the latent replication of the virus. Upon reactivation, the virus replicates in neuronal cell bodies, and virions shed from the cells which are carried down the nerve to the area of skin innervated by that ganglion. In the skin, the virus causes local inflammation and blistering. The pain caused by zoster is due to inflammation of affected nerves with the virus. Zoster characteristically presents with a prodrome of fever, malaise, and excruciating burning pain followed by the outbreak of vesicles that appear in one to three crops over three to five days. Lesions are distributed unilaterally within a single dermatome. Herpes zoster is clinically diagnosed with burning pain, characteristic morphology, and typical distribution. Antiviral therapy hastens the resolution of lesions, decreases acute pain and helps to prevent post-herpetic neuralgia especially in elderly patients. Acyclovir 800 mg, five times daily for five days, valacyclovir 1 gm three times daily for five days, and famciclovir 500 mg three times daily for seven days are the antiviral drugs used to treat herpes zoster.
'Herpes Zoster - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Herpes Zoster pipeline landscape is provided which includes the disease overview and Herpes Zoster treatment guidelines. The assessment part of the report embraces, in depth Herpes Zoster commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Herpes Zoster collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Herpes Zoster R&D. The therapies under development are focused on novel approaches to treat/improve Herpes Zoster.
This segment of the Herpes Zoster report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Herpes Zoster Emerging Drugs
- Varicella zoster virus vaccine: Changchun BCHT Biotechnology
- EG-HZ: EyeGene
- CRV1O1: Curevo Vaccine
Further product details are provided in the report……..
Herpes Zoster: Therapeutic Assessment
This segment of the report provides insights about the different Herpes Zoster drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Herpes Zoster
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical.
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Herpes Zoster: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Herpes Zoster therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Herpes Zoster drugs.
Herpes Zoster Report Insights
- Herpes Zoster Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Herpes Zoster drugs?
- How many Herpes Zoster drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Herpes Zoster?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Herpes Zoster therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Herpes Zoster and their status?
- What are the key designations that have been granted to the emerging drugs?
Introduction
Executive Summary
Herpes Zoster: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Varicella zoster virus vaccine: Changchun BCHT Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
EG-HZ: EyeGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
Comparative Analysis
GLS5100: Gene One Life Science
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Herpes Zoster Key Companies
Herpes Zoster Key Products
Herpes Zoster- Unmet Needs
Herpes Zoster- Market Drivers and Barriers
Herpes Zoster- Future Perspectives and Conclusion
Herpes Zoster Analyst Views
Herpes Zoster Key Companies
Appendix
Executive Summary
Herpes Zoster: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
Comparative Analysis
Varicella zoster virus vaccine: Changchun BCHT Biotechnology
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
EG-HZ: EyeGene
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical stage products
Comparative Analysis
GLS5100: Gene One Life Science
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Herpes Zoster Key Companies
Herpes Zoster Key Products
Herpes Zoster- Unmet Needs
Herpes Zoster- Market Drivers and Barriers
Herpes Zoster- Future Perspectives and Conclusion
Herpes Zoster Analyst Views
Herpes Zoster Key Companies
Appendix
LIST OF TABLES
Table 1 Total Products for Herpes Zoster
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Herpes Zoster
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Herpes Zoster
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Herpes Zoster
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
